ClinicalTrials.gg
Not yet recruitingNCT07165158Updated Sep 17, 2025

The Effect of Semaglutide on Bone Health

A Phase 4 interventional study of semaglutide combined with metformin in Osteoporosis, Osteoporosis Fracture and T2DM, sponsored by The First Affiliated Hospital of Xiamen University. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by The First Affiliated Hospital of Xiamen University · Phase 4, Interventional, and Screening

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
23rd of 57
150 · median 120
Started
2025
with 10 others
Phase 4
13 of 87
2 open now
Primary completion
2026-12
later than 21 of 32 live
Registered
77th of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 23rd largest by planned enrollment of the 57 interventional ones that give a count, is one of 11 that started in 2025, is one of 13 in phase 4, reaches primary completion later than 21 of the 32 other live ones, and was the 77th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

Semaglutide has effects that include lowering blood sugar, reducing weight, and improving cardiovascular and renal outcomes, and it is now widely used in clinical practice. Given that weight loss is associated with bone loss, its effect on bone health has recently raised concerns. Therefore, the goal of this clinical trial is to learn the effect of semaglutide on bone mineral density and fractures in patients with type 2 diabetes.

The investigators will compare semaglutide combined with metformin to metformin alone to see if semaglutide treatment has effects on bone mineral density and bone turnover markers in patients with type 2 diabetes after 12 months.

The intervention group will receive semaglutide combined with metformin for 12 months, while the control group will receive metformin alone for the same duration. After 12 months of treatment, the investigators will compare the bone mineral density, fracture incidence, and levels of bone turnover markers between the two groups.

03

Conditions studied

  • Osteoporosis
  • Osteoporosis Fracture
  • T2DM

Keywords

  • antidiabetic drug
  • osteoporosis fracture
  • T2DM
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetes (according to WHO diagnostic criteria),
  2. Age range: 50 to ≦75 years,
  3. Glycosylated (): 6.5 to ≦9.0%,
  4. Bone mineral density (lumbar spine, hip, or femoral neck) T-score \< -1, or history of fragility fractures (hip, vertebral, distal forearm, or proximal humerus fractures) within three years before screening,
  5. No use of antidiabetic medications in 8 weeks prior to enrollment (excluding metformin).

Exclusion criteria

Exclusion Criteria:

  1. Bone mineral density (lumbar spine, hip, or femoral neck) T-score \< -2.5,
  2. History of secondary osteoporosis,
  3. Serious liver dysfunction or chronic kidney disease ( (AST) or alanine transaminase (ALT) > 2.5 times the reference, or estimated (eGFR) \< 45 ml/min/1.73㎡),
  4. History of malignant tumors,
  5. Received strong anti-osteoporosis medications such as bisphosphonates, denosumab, or teriparatide within the past 2 years,
  6. History of pancreatitis or triglyceride levels >5.6 mmol/L;
  7. Family history of medullary carcinoma.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    The intervention group

    In the intervention group, the participants will receive semaglutide combined with metformin treatment.

    Drug: semaglutide combined with metformin

  • No intervention
    The control group

    In the control group, the participants will be treated with metformin alone (500mg each time, three times a day).

Interventions

  • Drugsemaglutide combined with metformin

    Drug pages: SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The initial dose of semaglutide is 0.25 mg once weekly. After 4 weeks, the dose is adjusted to 0.5 mg once weekly. After another 4 weeks, the dose is adjusted to 1 mg once weekly. During the same period, they will take metformin (500mg each time, three times a day) for treatment. The treatment course is 12 months.

06

What researchers measure

Primary outcomes

  1. lumbar bone mineral density

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 15 months is below that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 10, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07165158
Collaborators
Peking University First Hospital, Shanghai Punan Hospital of Pudong New District, Shanghai 6th People's Hospital, Jinzhou Medical University
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Xiulin Shi
Contact
shixiulin2022@163.com
0592-2139940

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Metformin

Start the discussion